0001642545-24-000012.txt : 20240118
0001642545-24-000012.hdr.sgml : 20240118
20240118201525
ACCESSION NUMBER: 0001642545-24-000012
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240116
FILED AS OF DATE: 20240118
DATE AS OF CHANGE: 20240118
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Godshall Douglas Evan
CENTRAL INDEX KEY: 0001404227
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38829
FILM NUMBER: 24543448
MAIL ADDRESS:
STREET 1: SUITE 4 LEVEL 46 2 PARK STREET
CITY: SIDNEY
STATE: C3
ZIP: 2000
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Shockwave Medical, Inc.
CENTRAL INDEX KEY: 0001642545
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
ORGANIZATION NAME: 08 Industrial Applications and Services
IRS NUMBER: 270494101
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
BUSINESS PHONE: (510) 279-4262
MAIL ADDRESS:
STREET 1: 5403 BETSY ROSS DRIVE
CITY: SANTA CLARA
STATE: CA
ZIP: 95054
FORMER COMPANY:
FORMER CONFORMED NAME: ShockWave Medical, Inc.
DATE OF NAME CHANGE: 20150515
4
1
wk-form4_1705626913.xml
FORM 4
X0508
4
2024-01-16
0
0001642545
Shockwave Medical, Inc.
SWAV
0001404227
Godshall Douglas Evan
C/O SHOCKWAVE MEDICAL, INC.
5403 BETSY ROSS DRIVE
SANTA CLARA
CA
95054
1
1
0
0
President & CEO
1
Common Stock
2024-01-16
4
M
0
10000
3.416
A
151057
D
Common Stock
2024-01-16
4
S
0
300
215.54
D
150757
D
Common Stock
2024-01-16
4
S
0
6150
216.87
D
144607
D
Common Stock
2024-01-16
4
S
0
1302
217.97
D
143305
D
Common Stock
2024-01-16
4
S
0
1248
219.27
D
142057
D
Common Stock
2024-01-16
4
S
0
1000
220
D
141057
D
Common Stock
2024-01-17
4
A
0
22078
0
A
163135
D
Common Stock
2024-01-18
4
F
0
10250
217.78
D
152885
D
Stock Option
3.416
2024-01-16
4
M
0
10000
0
D
2027-05-09
Common Stock
10000
304799
D
All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/25/2023.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $215.23 to $216.18. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $216.47 to $217.41. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $217.49 to $218.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $218.70 to $219.58. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $219.79 to $220.29. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
Represents the vesting and settlement of a performance-based restricted stock unit award granted on February 1, 2022, resulting from the achievement of certain performance criteria related to the compound annual growth rate of the Issuers revenue during the measurement period January 1, 2022 through December 31, 2023.
Fully vested.
/s/ Wade Estey, as attorney-in-fact for Douglas Godshall
2024-01-18